Currently, there are 11.79M common shares owned by the public and among those 11.48M shares have been available to trade.
The company’s stock has a 5-day price change of 156.23% and 44.44% over the past three months. PSTV shares are trading 24.35% year to date (YTD), with the 12-month market performance down to -21.43% lower. It has a 12-month low price of $0.24 and touched a high of $2.67 over the same period. PSTV has an average intraday trading volume of 15.67 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 53.71%, 30.63%, and 3.71% respectively.
Institutional ownership of Plus Therapeutics Inc (NASDAQ: PSTV) shares accounts for 16.02% of the company’s 11.79M shares outstanding.
It has a market capitalization of $16.85M and a beta (3y monthly) value of 0.67. The earnings-per-share (ttm) stands at -$2.24. Price movements for the stock have been influenced by the stock’s volatility, which stands at 80.63% over the week and 59.18% over the month.
Analysts forecast that Plus Therapeutics Inc (PSTV) will achieve an EPS of -0.5 for the current quarter, -0.36 for the next quarter and -1.61 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -0.58 while analysts give the company a high EPS estimate of -0.58. Comparatively, EPS for the current quarter was -0.7 a year ago. Earnings per share for the fiscal year are expected to increase by 56.01%, and 29.49% over the next financial year. EPS should shrink at an annualized rate of 33.56% over the next five years, compared to 68.20% over the past 5-year period.
Looking at the support for the PSTV, a number of firms have released research notes about the stock. D. Boral Capital stated their Buy rating for the stock in a research note on March 17, 2025, with the firm’s price target at $9. Ladenburg Thalmann coverage for the Plus Therapeutics Inc (PSTV) stock in a research note released on January 25, 2021 offered a Buy rating with a price target of $8.
